Nair Vidhya R, Malladi Srinivas
Department of Pathology, UT Southwestern Medical Center, Dallas, TX, USA.
Department of Pathology, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA.
Methods Mol Biol. 2019;1884:141-150. doi: 10.1007/978-1-4939-8885-3_9.
Metastatic latency is a major concern in the clinic, yet how these disseminated cancer cells survive and initiate metastases is unknown (Massagué and Obenauf, Nature 529:298-306, 2016). Here, we describe an approach to isolate latency competent cancer (LCC) cells from early stage human lung and breast carcinoma cell lines using mouse xenograft models (Malladi, Cell 165:45-60, 2016). Cancer cell lines labeled with GFP-luciferase and antibiotic selection markers were injected intracardially into athymic mice. Three months, post-injection, LCC cells were identified in situ and isolated. Upon reinjection, LCC cells retain their tumorigenic potential, enter a slow-cycling or quiescent state, and evade NK cell-mediated innate immune surveillance.
转移潜伏期是临床上的一个主要问题，但这些播散性癌细胞如何存活并引发转移尚不清楚（马萨诸塞和奥贝瑙夫，《自然》529:298 - 306，2016年）。在这里，我们描述了一种使用小鼠异种移植模型从早期人类肺癌和乳腺癌细胞系中分离具有潜伏能力的癌细胞（LCC）的方法（马拉迪，《细胞》165:45 - 60，2016年）。用绿色荧光蛋白 - 荧光素酶和抗生素选择标记物标记的癌细胞系经心内注射到无胸腺小鼠体内。注射后三个月，原位鉴定并分离出LCC细胞。再次注射后，LCC细胞保留其致瘤潜力，进入慢周期或静止状态，并逃避自然杀伤细胞介导的先天免疫监视。
